<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02002325</url>
  </required_header>
  <id_info>
    <org_study_id>NCVC-STROKE-001</org_study_id>
    <secondary_id>UMIN000011630</secondary_id>
    <nct_id>NCT02002325</nct_id>
  </id_info>
  <brief_title>THrombolysis for Acute Wake-up and Unclear-onset Strokes With Alteplase at 0.6 mg/kg Trial (THAWS)</brief_title>
  <acronym>THAWS</acronym>
  <official_title>THrombolysis for Acute Wake-up and Unclear-onset Strokes With Alteplase at 0.6 mg/kg Trial (THAWS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cerebral and Cardiovascular Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Charitable Trust Mihara Cerebrovascular Disorder Research Promotion Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Japan Agency for Medical Research and Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cerebral and Cardiovascular Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to clarify efficacy and safety of MRI-based intravenous&#xD;
      thrombolysis with alteplase for patients with acute wake-up ischemic stroke and those having&#xD;
      acute ischemic stroke with unknown time of symptom onset.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      THAWS is an investigator initiated Japanese multicenter randomized controlled clinical trial&#xD;
      of MRI based thrombolysis in patients with acute wake-up ischemic stroke and those having&#xD;
      acute ischemic stroke with unknown time of symptom onset. Intravenous thrombolysis with&#xD;
      alteplase of 0.6mg/kg, different from 0.9mg/kg used in other countries, is available as&#xD;
      effective and safe treatment of acute stroke within 4.5 hours of symptom onset in Japan.&#xD;
      However, time of symptom onset is unknown in about 25% of acute stroke patients. These&#xD;
      patients are currently excluded from intravenous thrombolysis with alteplase. The objective&#xD;
      of the THAWS project is to provide effective treatment options for acute stroke patients with&#xD;
      unknown time of symptom onset. The purpose of this study is to clarify efficacy and safety of&#xD;
      MRI-based intravenous thrombolysis with alteplase of 0.6mg/kg for patients with acute wake-up&#xD;
      ischemic stroke and those having acute ischemic stroke with unknown time of symptom onset.&#xD;
      Eligible patients will be selected based on MRI findings indicative of acute ischemic stroke&#xD;
      less than 4.5 hours of age.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">May 2014</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Modified Rankin Scale 0-1</measure>
    <time_frame>90 days after stroke onset</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Categorical shift in National Institutes of Health (NIHSS) score at 24 h</measure>
    <time_frame>24 hours after the initiation of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Categorical shift in NIHSS score at 7 days</measure>
    <time_frame>7 days after the initiation of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin Scale 0-2</measure>
    <time_frame>90 days after stroke onset</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Categorical shift in modified Rankin Scale score</measure>
    <time_frame>90 days after stroke onset</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parenchymal hemorrhage type-2 (PH-2)</measure>
    <time_frame>24 hours after the initiation of treatment</time_frame>
    <description>MRI proven SICH</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic intracranial hemorrhage (sICH) in SITS-MOST</measure>
    <time_frame>24 hours after the initiation of treatment</time_frame>
    <description>MRI proven SICH</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sICH as defined in European Cooperative Acute Stroke Study (ECASS) II</measure>
    <time_frame>24 hours after the initiation of treatment</time_frame>
    <description>MRI proven SICH</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sICH as defined in National Institute of Neurological Disorders and Stroke (NINDS)</measure>
    <time_frame>24 hours after the initiation of treatment</time_frame>
    <description>MRI proven SICH</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major bleeding</measure>
    <time_frame>Up to 90 days after stroke onset</time_frame>
    <description>Fatal bleeding, symptomatic bleeding in a critical area or organ, such as intraspinal, intraocular, retroperitoneal, intraarticular or pericardial, or intramuscular with compartment syndrome, or bleeding causing a fall in hemoglobin level of ≥2g/dL, or leading to transfusion of ≥4.5 units of whole blood or red cells according to the definition of the International Society on Thrombosis and Haemostasis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin Scale 6</measure>
    <time_frame>90 days after stroke onset</time_frame>
    <description>Death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infarct volume</measure>
    <time_frame>7 days after stroke onset</time_frame>
    <description>Infarct volume on FLAIR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infarct volume growth</measure>
    <time_frame>7 days after stroke onset</time_frame>
    <description>Infarct volume on FLAIR at 7 days minus infarct volume on DWI at baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>Alteplase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous tissue-type plasminogen activator (alteplase)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Standard treatment for acute stroke</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tissue-type plasminogen activator (alteplase)</intervention_name>
    <description>Intravenous tissue-type plasminogen activator (alteplase) 0.6mg/kg body-weight up to a maximum of 60 mg, 10% as bolus, 90% over 1 hour as infusion (plus other standard treatment if needed)</description>
    <arm_group_label>Alteplase</arm_group_label>
    <other_name>rt-PA</other_name>
    <other_name>Activacin</other_name>
    <other_name>Grtpa</other_name>
    <other_name>Actilyse</other_name>
    <other_name>Activase</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard care</intervention_name>
    <description>Standard treatment for acute stroke without intravenous alteplase.</description>
    <arm_group_label>Standard Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of acute ischemic stroke with unknown symptom onset (e.g. acute&#xD;
             wake-up ischemic stroke, acute ischemic stroke with unknown time of symptom onset)&#xD;
&#xD;
          -  Last known well without neurological symptoms &gt;4.5 hours of treatment initiation&#xD;
&#xD;
          -  Treatment can be started within 4.5 hours of symptom recognition (e.g. awaking)&#xD;
&#xD;
          -  Acute stroke MRI including diffusion weighted imaging (DWI) and fluid attenuated&#xD;
             inversion recovery (FLAIR) completed&#xD;
&#xD;
          -  Alberta Stroke Program Early CT score (ASPECTS) on initial DWI is 5 or more&#xD;
&#xD;
          -  No marked parenchymal hyperintensity visible on FLAIR&#xD;
&#xD;
          -  Initial NIHSS ≥2&#xD;
&#xD;
          -  Written informed consent by patient or next of kin&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pre-stroke Modified Rankin Scale (mRS) &gt;1 (patients who have inability to carry out&#xD;
             all daily activities and require some help or supervision)&#xD;
&#xD;
          -  Contraindications in the Japanese guideline for the intravenous application of&#xD;
             recombinant tissue-type plasminogen activator (alteplase)&#xD;
&#xD;
               -  History of nontraumatic intracranial hemorrhage&#xD;
&#xD;
               -  History of stroke within the last 1 month (excluding transient ischemic attack)&#xD;
&#xD;
               -  History of significant head/spinal injury or surgery within the last 3 months&#xD;
&#xD;
               -  History of gastrointestinal or urinary tract bleeding within the last 21 days&#xD;
&#xD;
               -  History of major surgery or significant trauma other than head injury within the&#xD;
                  last 14 days&#xD;
&#xD;
               -  Hypersensitivity to alteplase&#xD;
&#xD;
               -  Suspected subarachnoid hemorrhage&#xD;
&#xD;
               -  Concurrent acute aortic dissection&#xD;
&#xD;
               -  Concurrent hemorrhage (e.g., intracranial, gastrointestinal, urinary tract, or&#xD;
                  retroperitoneal, hemoptysis)&#xD;
&#xD;
               -  Systolic blood pressure ≥185 mmHg despite antihypertensive therapy&#xD;
&#xD;
               -  Diastolic blood pressure ≥110 mmhg despite antihypertensive therapy&#xD;
&#xD;
               -  Significant hepatic disorder&#xD;
&#xD;
               -  Acute pancreatitis&#xD;
&#xD;
               -  Blood glucose &lt;50mg/dL or &gt;400 mg/dL&#xD;
&#xD;
               -  Platelet count ≤100,000/mm3&#xD;
&#xD;
               -  International normalized ratio of prothrombin time (PT-INR) &gt;1.7 or Prolonged&#xD;
                  activated partial thromboplastin time (aPTT: &gt;1.5 times the baseline value&#xD;
                  [&gt;approximately 40 seconds only as a guide]) for patients on anticoagulation&#xD;
                  therapy or those with abnormal coagulation&#xD;
&#xD;
          -  Any contraindication to MRI (e.g. cardiac pacemaker)&#xD;
&#xD;
          -  Extensive early ischemic change in brain stem or cerebellum (e.g., more than half of&#xD;
             brain stem or more than one hemisphere of cerebellum)&#xD;
&#xD;
          -  Planned or anticipated treatment with surgery or endovascular reperfusion strategies&#xD;
             (e.g., intra-arterial thrombolysis, mechanical recanalization techniques)&#xD;
&#xD;
          -  Pregnant, lactating, or potentially pregnant&#xD;
&#xD;
          -  Life expectancy 6 months or less by judgment of the investigator&#xD;
&#xD;
          -  Inappropriate for study enrollment by judgment of the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kazunori Toyoda, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cerebral and Cardiovascular Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Cerebral and Cardiovascular Center</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <zip>565-8565</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://onlinelibrary.wiley.com/doi/10.1111/ijs.12360/abstract;jsessionid=763C32F84872E896DA9F27975D7843B6.f01t04</url>
    <description>THrombolysis for Acute Wake-up and unclear-onset Strokes with alteplase at 0·6 mg/kg (THAWS) Trial</description>
  </link>
  <reference>
    <citation>Koga M, Toyoda K, Kimura K, Yamamoto H, Sasaki M, Hamasaki T, Kitazono T, Aoki J, Seki K, Homma K, Sato S, Minematsu K; THAWS investigators. THrombolysis for Acute Wake-up and unclear-onset Strokes with alteplase at 0·6 mg/kg (THAWS) Trial. Int J Stroke. 2014 Dec;9(8):1117-24. doi: 10.1111/ijs.12360. Epub 2014 Aug 4.</citation>
    <PMID>25088843</PMID>
  </reference>
  <reference>
    <citation>Toyoda K, Koga M, Hayakawa M, Yamagami H. Acute reperfusion therapy and stroke care in Asia after successful endovascular trials. Stroke. 2015 Jun;46(6):1474-81. doi: 10.1161/STROKEAHA.115.008781. Epub 2015 May 5. Review.</citation>
    <PMID>25944322</PMID>
  </reference>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>November 28, 2013</study_first_submitted>
  <study_first_submitted_qc>November 28, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2013</study_first_posted>
  <last_update_submitted>December 18, 2018</last_update_submitted>
  <last_update_submitted_qc>December 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cerebral and Cardiovascular Center</investigator_affiliation>
    <investigator_full_name>Kazunori Toyoda</investigator_full_name>
    <investigator_title>Director and Chair, Department of Cerebrovascular Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
    <mesh_term>Plasminogen</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>April 21, 2020</submitted>
    <returned>May 5, 2020</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

